UCSF Launches Translational Psychedelic Research (TrPR) Program April 9, 2021
The newly christened Translational Psychedelic Research (TrPR) Program is launching a unique multidisciplinary network of scientists and healthcare providers who work together to research psychedelic-assisted therapies.
The TrPR Program, which is based at UCSF, is distinguishing itself from other university research groups through its distinctively inclusive approach to psychedelic medicine. Members of the TrPR network study psychedelic therapies that may benefit patients with conditions considered higher risk or overlooked by other researchers in the field, such as bipolar disorder, Parkinson’s and back pain.
TrPR includes investigators from both clinical and research disciplines based at medical centers from the San Francisco Bay Area to Seattle, says Dr. Joshua Woolley Associate Professor of Psychiatry at the UCSF Weill Institute for Neurosciences and Director of the Translationa
Subscribe
Investing in the Future of Food: VMG Partners raises $850m to invest in CPGs with potential to be iconic By Elizabeth Crawford Known for its strong track record of helping emerging brands, like KIND, Bare Snacks and Spindrift, become household names, private equity firm VMG Partners is on the lookout once again for new investment opportunities after securing $850m for its Growth Fund V.
As in the past, VMG’s Growth Fund is seeking
“a small handful” of early- and later-stage consumer brands in the food & beverage, wellness, beauty & personal care and pet sectors that support consumers on their incremental health journey and which hold the potential to become iconic brands.